期刊
FRONTIERS IN ONCOLOGY
卷 8, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2018.00039
关键词
cancer; glycosylation; fucosylation; fucosyltransferases; Lewis antigens
类别
资金
- European Union (Marie Curie European Training Network), GlyCoCan project [676421]
- IMMUNOSHAPE project [642870]
- Dutch Cancer Society (KWF) [6779-VU-2014]
- ERC (Glycotreat) [339977]
- European Research Council (ERC) [339977] Funding Source: European Research Council (ERC)
Aberrant glycosylation of tumor cells is recognized as a universal hallmark of cancer pathogenesis. Overexpression of fucosylated epitopes, such as type I (H1, Lewis(a), Lewis(b), and sialyl Lewis(a)) and type II (H2, Lewis(x), Lewis(y), and sialyl Lewis(x)) Lewis antigens, frequently occurs on the cancer cell surface and is mainly attributed to upregulated expression of pertinent fucosyltransferases (FUTs). Nevertheless, the impact of fucose-containing moieties on tumor cell biology is not fully elucidated yet. Here, we review the relevance of tumor-overexpressed FUTs and their respective synthesized Lewis determinants in critical aspects associated with cancer progression, such as increased cell survival and proliferation, tissue invasion and metastasis, endothelial to mesenchymal transition, endothelial and immune cell interaction, angiogenesis, multidrug resistance, and cancer stemness. Furthermore, we discuss the potential use of enhanced levels of fucosylation as glycan biomarkers for early prognosis, diagnosis, and disease monitoring in cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据